• 43 studies were included in this meta-analysis; 19 of them reported fracture outcomes for males.
• There was very little evidence of heterogeneity (Total population: I2=0.0%; Male population: I2=11.9%-15.3%). No differences were found for fixed effects model and random effects model.
• A visual inspection of the funnel plots and the Egger's tests (Total population: p=0.119; Male population: p=0.690) indicated no evidence of publication bias.
• Meta-regression showed that male proportion, age, BMI, BMD Tscore at lumbar spine, femoral neck, and total hip sites, were unrelated to the effect size of bisphosphonates on fracture outcome 
BISPHOSPHONATES FOR FRACTURE PREVENTION IN MALES -A SYSTEMATIC REVIEW AND META-ANALYSIS

Background
• The prevalence of osteoporosis and osteopenia is about 0.8 million and 11.8 million, respectively, in men older than 50 years. 1 • About 13-22 percent of men develop at least one osteoporotic fracture during their lifetime. 2 • The risk of hip fracture by age and bone mineral density (BMD) is similar in men and women; however, hip fracture poses a higher mortality risk in men. 3 • In men with low BMD and at risk of facture, less than 10% received treatment for osteoporosis. 4 • There is a lack of randomized controlled trials (RCTs) to confirm the efficacy of bisphosphonates for fracture prevention in males.
Objectives
• The objective of this systematic review and meta-analysis is to assess the efficacy of bisphosphonate therapy in the prevention of vertebral and non-vertebral fractures in males at risk for fracture receiving these agents compared to placebo.
Methods Database Search
• MEDLINE/PubMed, The Cochrane Central Register of Controlled Trials in the Cochrane Library, Scopus, Clinicaltrials.gov, and EMBASE without language restriction Selection Criteria
• Types of studies: RCTs with duration of at least one year
• Participants: Adult male participants at risk for fracture. RCTs that contained both men and women that reported the number of males were also included.
• • Assessment of Study Quality: Potential sources of bias including sequence generation, allocation concealment, blinding, and attrition via the criteria specified by the Cochrane Collaboration.
Analysis
• Relative risk (RR) of all reported fracture outcomes (any, clinical vertebral, morphometric vertebral, non-vertebral, hip) with 95% confidence intervals (CI) for each study was calculated.
• Data were pooled using both fixed effects and random effects models.
• Statistical heterogeneity was assessed using a chi-squared test with significance set at a p-value of 0.10 and the I 2 test with substantial heterogeneity defined as I 2 > 50%.
• Publication bias was examined using funnel plots and Egger's test.
• Subgroup analyses were also conducted by study period (12 months vs 24 months), specific drug treatment, primary/secondary osteoporosis, and potential sources of bias.
• Meta-regressions were run to examine the impact of age, BMI, T scores, prior fractures, and proportion male on the effect size.
• A two-sided p-value ≤0.05 was considered statistically significant. All analyses were performed using Stata 13.1. 
